Patient Identification for TEPEZZA

TEPEZZA demonstrated results in patients with varied clinical presentations of Thyroid Eye Disease (TED)1,2

Proven safety icon Proven safety icon

Get your patients started on TEPEZZA

Learn more about prescribing TEPEZZA

1. Diniz SB, Cohen LM, Roelofs KA, Rootman DB. Early experience with the clinical use of teprotumumab in a heterogenous thyroid eye disease population. Ophthalmic Plast Reconstr Surg. 2021;37(6):583-591. 2. Ugradar S, Kang J, Kossler AL, et al. Teprotumumab for the treatment of chronic thyroid eye disease. Eye (Lond). 2021. Published online July 9, 2021. doi:10.1038/s41433-021-01593-z. 3. Douglas RS, Kahaly GJ, Patel A, et al. Teprotumumab for the treatment of active thyroid eye disease. N Engl J Med. 2020;382(4):341-352. 4. Data on File. Horizon, January 2020. 5. Ozzello DJ, Dallalzadeh LO, Liu CY. Teprotumumab for chronic thyroid eye disease. Orbit. 2021:1-8. Published online June 1, 2021. doi:10.1080/01676830.2021.1933081. 6. Douglas RS, Kahaly GJ, Ugradar S, et al. Teprotumumab efficacy, safety and durability in longer duration thyroid eye disease and retreatment: OPTIC-X study. Ophthalmology. Published online October 21, 2021. doi:10.1016/j.ophtha.2021.10.017